Dasyo Welcomes Medical Aesthetics Industry Icon Domenic Serafino (Dom) as Executive Chair

Dasyo, a company pioneering innovative noninvasive technologies in medical aesthetics, is thrilled to announce the appointment of Domenic Serafino (Dom) as Executive Board Chair.

Dasyo is developing groundbreaking non-surgical breast lifts product using proprietary technology for noninvasive directional skin tightening. Dasyo is funded by the Israel Innovation Authority and The Trendlines Group (SGX: 42T) (OTCQX: TRNLY).

Dom’s impressive track record includes Co-Founder and CEO of Venus Concept Inc. from inception in 2010 through 2022. He led the company from startup to over $100 million in annual revenues.

Domenic Serafino was part of the start-up executive team at Syneron Medical Corp acting as its President of North America and Executive Vice President – Syneron Medical Israel. He was instrumental in helping Syneron IPO in 2004, reaching a market cap of $1.3 billion less than 18 months from IPO.

Dom also served as President and Chief Operating Officer of Sigmacon Group, Canada’s largest laser distribution company, from 1994 through 2001.

“Welcoming Dom as Executive Chair is a transformative step for Dasyo,” stated Emri Valtzer, CEO of Dasyo. “His visionary leadership and unmatched expertise in the aesthetics medical device arena are perfectly aligned with our ambitious objectives. We are thrilled to have him on our board and are eager to harness his insights to propel our innovative vision.”

“I am honored to join Dasyo as Executive Chair,” shared Dom Serafino. “Dasyo’s dedication to pioneering aesthetics medical technologies is truly commendable. After researching and working with many different technologies over the years, I am confident that the team at Dasyo has truly developed something new and innovative in the directional skin tightening category, especially in non-surgical breast lifting.”

Serafino’s appointment significantly enhances Dasyo’s strategic direction and growth potential, reinforcing the company’s commitment to innovation and excellence in the noninvasive aesthetics medical device sector.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”